These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1903732)

  • 1. Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization.
    Maroulis GB; Emery M; Verkauf BS; Saphier A; Bernhisel M; Yeko TR
    Fertil Steril; 1991 Jun; 55(6):1157-64. PubMed ID: 1903732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of cryopreserved pre-embryos obtained in in vitro fertilization cycles with or without a gonadotropin-releasing hormone agonist.
    Oehninger S; Toner JP; Veeck LL; Brzyski RG; Acosta AA; Muasher SJ
    Fertil Steril; 1992 Mar; 57(3):620-5. PubMed ID: 1740208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrashort gonadotropin-releasing hormone agonist (GnRH-a) protocol in comparison with the long-acting GnRH-a protocol and menotropin alone.
    Ron-El R; Herman A; Golan A; Soffer Y; Nachum H; Caspi E
    Fertil Steril; 1992 Dec; 58(6):1164-8. PubMed ID: 1459267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels.
    Ben-Rafael Z; Lipitz S; Bider D; Mashiach S
    Fertil Steril; 1991 Feb; 55(2):272-5. PubMed ID: 1825069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The routine use of gonadotropin-releasing hormone agonists for all patients undergoing in vitro fertilization. Is there any medical advantage? A prospective randomized study.
    Kingsland C; Tan SL; Bickerton N; Mason B; Campbell S
    Fertil Steril; 1992 Apr; 57(4):804-9. PubMed ID: 1555691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.
    Younis JS; Simon A; Koren R; Dorembus D; Schenker JG; Laufer N
    Fertil Steril; 1992 Sep; 58(3):575-80. PubMed ID: 1387849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins.
    Caspi E; Ron-El R; Golan A; Nachum H; Herman A; Soffer Y; Weinraub Z
    Fertil Steril; 1989 Jan; 51(1):95-9. PubMed ID: 2521328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.
    Penzias AS; Shamma FN; Gutmann JN; Seifer DB; DeCherney AH; Lavy G
    J Assist Reprod Genet; 1992 Jun; 9(3):244-7. PubMed ID: 1525454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization.
    Garcia JE; Padilla SL; Bayati J; Baramki TA
    Fertil Steril; 1990 Feb; 53(2):302-5. PubMed ID: 2105247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization.
    Segal S; Casper RF
    Fertil Steril; 1992 Jun; 57(6):1254-8. PubMed ID: 1601147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative success of gonadotropin-releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in vitro fertilization.
    Dor J; Ben-Shlomo I; Levran D; Rudak E; Yunish M; Mashiach S
    Fertil Steril; 1992 Nov; 58(5):986-90. PubMed ID: 1426387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of GnRH analogue therapy in IVF in women with unexplained infertility.
    Ashkenazi J; Dicker D; Feldberg D; Goldman GA; Yeshaya A; Goldman JA
    Hum Reprod; 1989 Aug; 4(6):667-9. PubMed ID: 2528570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF).
    Gonen Y; Dirnfeld M; Goldman S; Koifman M; Abramovici H
    J In Vitro Fert Embryo Transf; 1991 Oct; 8(5):254-9. PubMed ID: 1836810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteal phase consequences of low-dose gonadotropin-releasing hormone agonist therapy in nonluteal-supported in vitro fertilization cycles.
    Long CA; Sopelak VM; Lincoln SR; Cowan BD
    Fertil Steril; 1995 Sep; 64(3):573-6. PubMed ID: 7641913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.